PAX4 and Hyperglycemia: Consistent with previous reports exploiting the RIP-B7.1 model, 90–100% of immunised non-DOX-treated RIP-B7.1 mice bearing either the Pax4 or Pax4R129W transgene developed hyperglycaemia within 3 weeks, correlating with insulitis and beta cell destruction [33].